Notice: Undefined index: HTTP_ACCEPT_LANGUAGE in C:\inetpub\wwwroot\technology_detail.php on line 331
 Technology Detail


The Office of Technology Licensing was established in 1970 to transfer technologies developed at Stanford. Find out more about OTL's history, mission, staff, and statistics.

Login to TechFinder » 

Immunomodulatory Therapy for Pulmonary Hypertension


Stanford Reference:

13-294


Abstract


This invention is comprised of a new cell-based immunomodulatory therapy using regulatory macrophages (Mreg) to prevent right ventricular dysfunction caused by pulmonary hypertension. Chronic pulmonary hypertension inevitably results in right ventricular (RV) dysfunction despite current optimal care management, and patients actually die from severe RV dysfunction rather than from damages of the pulmonary vasculature. Mregs are specific subset of macrophages that show anti-inflammatory properties that may ameliorate heart failure pathophysiology. Mregs are a particularly suitable cell type for use in clinical strategies because they are easily and reliably generated from peripheral blood monocytes and can be safely administered back into the patient by central venous infusion.

Applications


  • Clinical therapy: Prevention of pulmonary hypertension and right ventricle failure

Advantages


  • First-in-class: There is currently no cell-based therapeutic option for pulmonary hypertension patients

Publications



Innovators & Portfolio


  • Sonja Schrepfer   

Date Released

 3/25/2016
 

Notice: Undefined offset: 0 in C:\inetpub\wwwroot\technology_detail.php on line 1350

Licensing Contact


Denise Lew, Licensing Associate
650-725-3476 (Business)
Request Info

[-] Map/Timeline

96-103 εPKC Agonists to Provide Cardioprotection
97-059 Development of a Regulatable Retroviral-Vector System for Identification of Untranslated Regions of mRNAs
00-021 Mouse Model for Hypertension and for Drug Screening of Antihypertensive Drugs

more technologies »

Related Keywords


cardiovascular   pulmonary hypertension   cell-based therapy   right ventricle failure   cardiovascular; cell therapy   therapeutic: cardiovascular   
 

   

  

Also of Interest...
96-103 εPKC Agonists to Provide Cardioprotection
97-059 Development of a Regulatable Retroviral-Vector System for Identification of Untranslated Regions of mRNAs
00-021 Mouse Model for Hypertension and for Drug Screening of Antihypertensive Drugs

Recently Viewed...
S13-294 Immunomodulatory Therapy for Pulmonary Hypertension